annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 36G Phase I/II personalized therapy trial for metastatic colorectal cancer using
functional pathway mapping: Stratification to imatinib therapy. (Abstract
#TPS194)
M. Pierobon, S. Banks, A. Silvestri, G. Gambara, J. Wiedemann, L. A. Liotta, E.
Petricoin III, K. H. Edmiston, A. I. Spira
Brd. 36H SPIRITT: A multicenter, open-label, randomized, phase II clinical trial
evaluating safety and efficacy of FOLFIRI with either panitumumab or
bevacizumab as second-line treatment in patients with metastatic colorectal
cancer (mCRC) with wild-type KRAS tumors. (Abstract #TPS195)
A. L. Cohn, K. Krishnan, J. R. Hecht
Brd. 37A Induction chemotherapy with or without chemoradiation in intermediate-risk
rectal cancer patients defined by magnetic resonance imaging (MRI): A
GEMCAD study. (Abstract #TPS196)
C. Fernandez-Martos, M. Safont, J. Feliu, C. Pericay, M. Gallen, R. Vera, J.
Maurel, J. Aparicio, M. P. Escudero, G. Brown, GEMCAD
Brd. 37B Yttrium microspheres with cetuximab plus irinotecan for patients with
advanced colorectal cancer metastases to liver. (Abstract #TPS197)
R. Murthy, A. Mahvash, R. Avritscher, W. Erwin, B. Chasen, C. Eng
Brd. 37C Optimal control of liver metastases with intravenous cetuximab and hepatic
artery infusion of three-drug chemotherapy in patients with liver-only
metastases from colorectal cancer: A European multicenter phase II trial.
(Abstract #TPS198)
F. Levi, M. Bouchahda, M. Ducreux, A. Karaboué, C. N. Focan, P. Rougier, P.
Innominato, D. Smith, S. Awad, R. Adam
Brd. 37D The PARSC trial, a prospective study for the assessment of recurrence risk
in stage II colon cancer (CC) patients using ColoPrint. (Abstract #TPS199)
R. Salazar, J. Marshall, L. Stork-Sloots, I. Simon, M. Lutke Holzik, J. Tabernero,
J. J. Van Der Hoeven, F. Bibeau, R. Rosenberg
Gastrointestinal (Noncolorectal) Cancer
Brd. 37E Perioperative chemotherapy plus bevacizumab with early salvage therapy
based on PET response in patients with locally advanced resectable
gastric/GEJ cancer. (Abstract #TPS200)
E. C. Smyth, H. Schöder, D. G. Coit, V. E. Strong, M. F. Brennan, Y. Y. Janjigian,
M. Capanu, L. H. Tang, D. P. Kelsen, M. A. Shah
Brd. 37F Phase I study of sunitinib with irinotecan/5-fluorouracil/ leucovorin (FOLFIRI)
for advanced gastroesophageal cancers. (Abstract #TPS201)
N. I. Khushalani, G. J. Fetterly, R. V. Iyer, A. Litwin, W. Brady, M. M. Javle
Brd. 37H Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric
and esophageal (GE) adenocarcinoma. (Abstract #TPS203)
J. Li, J. S. Kortmansky, M. Saif, N. A. Fischbach, L. Ravage-Mass, K. Elligers, C.
Hahn, M. K. Cohenuram, J. Lacy
Brd. 38A A phase II trial of combined treatment of endoscopic mucosal resection
(EMR) and chemoradiotherapy (CRT) for clinical stage I esophageal
squamous cell carcinoma (ESCC): Japan Clinical Oncology Group study
JCOG0508. (Abstract #TPS204)
T. Tsuchida, M. Muto, K. Minashi, H. Ono, Y. Morita, R. Ishihara, I. Toshiro, H.
Kawai, N. Boku, H. Fukuda
Brd. 38B Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing
first-line metastatic gastric cancer (GC): A phase II randomized placebo
controlled trial (EORTC 40071). (Abstract #TPS205)
A. Roth, M. H. Moehler, M. Mauer, A. Schad, M. Karrasch, M. Praet, M. L. Lim, A.
Das-Gupta, M. P. Lutz
Brd. 38C Phase II study of irinotecan plus panitumumab as second-line therapy for
patients with advanced esophageal adenocarcinoma (EAC). (Abstract
#TPS206)
A. Atasoy, H. Yoon, A. M. Egloff, R. L. Ferris, A. H. Zaidi, B. Hough, A. A.
Forastiere, B. A. Jobe, K. S. Nason, M. K. Gibson
322